ARTIDIS Meets Primary Endpoints in First Prospective Study

Our portfolio company ARTIDIS announces today promising data from their first prospective study conducted at the Breast Center in Basel, Switzerland. The spin-off from the Biozentrum at the University of Basel has succesfully developed the first nanomechanical biomarker for cancer diagnosis and treatment optimization. 




HEMEX AG is a privately-owned Swiss investment and consulting company headquartered close to the Basel global life sciences hub, with its main focus to bring innovative drugs, medical devices and in vitro diagnostics to the market. HEMEX specializes in supporting early-stage start-ups, offering tailored solutions to accelerate the project into a successful and sustainable business. Additionally, HEMEX helps start-ups in their efforts to find non-dilutive and dilutive funding. More at

DayOne supports 6 digital health startups

DayOne accelerator program for digital health startups

Following their hard work in developing innovative solutions that promote the health of children and young people, 6 digital health startups:Zoundream, Haako, Rekonas (eTomo), Wello Health, Virtual Doctors and Nutrix, were selected for DayOne Accelerator program, which is managed by

At HEMEX, we are especially proud of our partners from Haako, Moritz Dietsche and Marko Kocic. Their mobile solution Breathe helps families with children affected by asthma to better manage their conditions.

To read more about the DayOne Accelerator and participants, please click here.


HEMEX Pitch Series

Swiss startup Scailyte CEO Peter Nestorov presenting at Hemex pitch event

At HEMEX, we regularly organize invitation-only pitch days, where selected startups get the opportunity to pitch in front of potential investors.

The focus of our last 2019 pitch session was on startups seeking to revolutionize cancer diagnosis and treatment. Thank you Christina Vallgren, Marcus Palm, Martin Stauber, Seline Eisenring, Michael Krauthammer and Peter Nestorov for introducing cutting edge oncology research and development activities for earlier cancer detection and targeted treatment with tremendous benefits for both patients and oncologists.

Would you like to receive your personalized invitation to one of our next sessions?

Or would you like to learn how to create a great pitch deck that gets potential investors excited about your idea and engages them in a conversation on how to invest in your business?

Please contact our start-up coach Franziska Stemmler for more information.


CEO Christina Vallgren of Terapet SA is presenting at Hemex pitch event

Swiss startup Scailyte CEO Peter Nestorov presenting at Hemex pitch event

Seline Eisenring is presenting at Hemex pitch event



HEMEX expands to China

Hemex CEO Pascal Winnen joined a visit to Henan China technology park

On 14th November 2019, our CEO Pascal Winnen signed a cooperation agreement with the Luoyang Science and Innovation Park in Henan, China’s most populated province.

Under the Agreement, HEMEX will support the property developer Forton Group with attracting innovative Swiss startups for its newly built 133’000 m2 life science park. In exchange, HEMEX and its clients will get access to Henan’s 108 million population to conduct clinical trials and receive governmental support to accelerate preclinical and clinical development projects, as well as granted access to significant non-dilutive research funding.

A big thank you to Dr. Robert Sum of the Standortförderung BL for leading this very efficient economic mission.